The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large XXXX in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.

@entity1 @entity632 @entity229 @entity786 @entity1892 @entity1891
BACKGROUND: The current standard therapy for @entity1 with @entity1892 ( @entity1892 ) is rituximab plus @entity786 , @entity632 , @entity1891 and @entity229 (RCHOP). The role of radiotherapy (RT) after complete response (CR) to RCHOP in @entity1 with @entity1892 remains unclear. This systematic review with a meta-analysis is an attempt to evaluate this role. METHODS: Studies that evaluated RT versus no-RT after CR to RCHOP for @entity1892 @entity1 were searched in databases. Hazard ratios (HR) with their respective 95% confidence intervals (CI) were calculated using a random-effects model. RESULTS: A total of 4 qualified retrospective studies (633 @entity1 ) were included in this review. The results suggested that RT improved overall survival (OS; HR 0.33, 95% CI 0.14-0.77) and progression-free/event-free survival (PFS/EFS; HR 0.24, 95% CI 0.11-0.50) in all @entity1 compared with no-RT. In a subgroup analysis of @entity1 with stage III-IV @entity1892 , RT improved PFS/EFS (HR 0.19, 95% CI 0.07-0.51) and local control (HR 0.12, 95% CI 0.03-0.44), with a trend of improving OS (HR 0.35, 95% CI 0.12-1.05). CONCLUSION: Consolidation RT could significantly improve outcomes of @entity1892 @entity1 who achieved a CR to RCHOP. However, the significance of these results was limited by these retrospective data. Further investigation of the role of consolidation RT in the rituximab era is needed.    2015 S. Karger AG, Basel.
